On November 1-2, 2018, the Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC) convened a 1.5-day consultative meeting on “Present and Future of Dengue Vaccines” in New Orleans, Louisiana, USA.

The objectives of this meeting were to update and review issues related to the development of dengue vaccines including the use of the currently licensed dengue vaccine, Dengvaxia®, and to identify critical points for consideration for the future of dengue vaccine development. The meeting was sponsored by Bill & Melinda Gates Foundation, Sanofi Pasteur, and Takeda Pharmaceuticals International AG.

"> On November 1-2, 2018, the Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC) convened a 1.5-day consultative meeting on “Present and Future of Dengue Vaccines” in New Orleans, Louisiana, USA.

The objectives of this meeting were to update and review issues related to the development of dengue vaccines including the use of the currently licensed dengue vaccine, Dengvaxia®, and to identify critical points for consideration for the future of dengue vaccine development. The meeting was sponsored by Bill & Melinda Gates Foundation, Sanofi Pasteur, and Takeda Pharmaceuticals International AG.

" /> 2018 GDAC Symposium: Present and Future Dengue Vaccines - Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC)
  • news

    2018 GDAC Symposium: Present and Future Dengue Vaccines

November 1-2, 2018 - New Orleans (USA)

On November 1-2, 2018, the Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC) convened a 1.5-day consultative meeting on “Present and Future of Dengue Vaccines” in New Orleans, Louisiana, USA.

The objectives of this meeting were to update and review issues related to the development of dengue vaccines including the use of the currently licensed dengue vaccine, Dengvaxia®, and to identify critical points for consideration for the future of dengue vaccine development. The meeting was sponsored by Bill & Melinda Gates Foundation, Sanofi Pasteur, and Takeda Pharmaceuticals International AG.